Algeta ASA | Date: 2014-02-19
The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such that an acceptably non-myelotoxic quantity of radium-223 is generated in vivo by nuclear decay of the administered thorium-227.
Algeta ASA | Date: 2013-05-13
A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group.
Algeta ASA | Date: 2012-03-29
A pharmaceutical preparation comprising at least one complexed alpha-emitting radionuclide and at least one polysaccharide biopolymer.
Algeta ASA | Date: 2011-02-14
The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.
Algeta ASA | Date: 2012-07-12
The present invention relates to a container for liquids, a method of filling it and the use of the container according to the invention for holding and storing radioactive substances. The container for a liquid comprises a cavity for holding the liquid, the cavity being bounded by walls (